Clinical Trial

A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, open label, cyclosporine controlled Phase II trial aimed at evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of Zuberitamab in patients with primary membranous nephropathy, and exploring the Phase III dosing regimen, sample size, and endpoint evaluation time
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-13.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-11-18
Trial Details
NCT Number NCT06642909
Lead Sponsor BioRay Pharmaceutical Co., Ltd.
Conditions Primary Membranous Nephropathy
Enrollment 135 participants
Start Date 2024-11-13
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-05-10 (estimated)
Updated on ClinicalTrials.gov 2025-11-20